GlassScriptPhysician profile
Varun Kumar Chukka
NPI 1194159293
$1,415.13
in general payments reported to CMS, 2019-2025
20 companies · $79.15 in 2025
The $79.15 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $86.48 · 2021: $54.78 · 2022: $326 · 2023: $498 · 2024: $152 · 2025: $79.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $728.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $241.66 | 2022-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Janssen Pharmaceuticals, INC | $241.15 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $177.09 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Novartis Pharmaceuticals Corporation | $133.63 | 2019-2023 | |
| Pfizer INC. | $99.12 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $85.40 | 2019-2021 | |
| Abbvie INC. | $77.73 | 2022 | |
| Alexion Pharmaceuticals, INC. | $55.93 | 2021-2023 | Ultomiris |
| Argenx US, INC. | $49.91 | 2023 | Vyvgart |
| Amgen INC. | $41.63 | 2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $33.96 | 2023-2024 | Enhertu, Farxiga |
| Melinta Therapeutics, LLC | $28.71 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.61 | 2025 | Jardiance |
| Ucb, INC. | $23.34 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $22.07 | 2023 | Camzyos |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $19.92 | 2023 | Padcev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.82 | 2023 | Xifaxan |
| Bioxcel Therapeutics, INC. | $15.73 | 2023 | Igalmi |
| Masimo Corporation | $14.24 | 2022 | |
| Sensible Medical Innovations INC | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Varun Chukka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.